Our study revealed that PROTAC treatment is also very useful and efficient in luminal p53-mutated BC cells as well, whereas the mdm2 inhibitor AMG-232 was practically ineffectual in inhibiting the cell cycle progress in p53 defective cells. The gene discussed is MDM2; the disease is breast cancer.